PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy, covering 2025-04-10 to 2025-04-10. Get the full timeline:
Most recent: Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) [Phase 3]